Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Includes OTCs In Bid For Dramatic Growth By 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.

You may also be interested in...



Valeant Keeps Door Open For Consumer Products Acquisitions

The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.

Valeant Keeps Door Open For Consumer Products Acquisitions

The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.

Deals Of The Week: Allena/Althea, Almirall/Menarini, Bausch & Lomb/Ista

Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel